Wren Medical Systems

Wren Laboratories (formerly known as Wren Medical Systems) is a molecular diagnostics company that developed the first clinically validated liquid biopsy for neuroendocrine tumors (NETs). The company's flagship product, the NETest, utilizes a proprietary PCR-based platform to measure a 51-gene multigene signature in the blood, providing a real-time assessment of tumor biological activity and treatment efficacy. This transcriptomic approach offers significantly higher sensitivity and specificity than traditional imaging or single-analyte biomarkers like Chromogranin A, enabling earlier detection of recurrence and more precise monitoring of disease progression. Based on research from Yale University, the company is currently expanding its diagnostic platform to include specialized tests for lung and prostate cancers.